Overview

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Eligibility

Inclusion Criteria:

• Men or women between ≥19 and ≤65 years of age at the time of informed consent
• Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
• Current episode of hair loss for ≥6 months but <8 years
• Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
• Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

Exclusion Criteria:

• Participants with the following medical history confirmed during screening:
  • ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
• Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp

  condition that may interfere with the SALT assessment

• Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors